mHealth Biometrics for Sedentary People (MotivateLJMU)

Sponsor
Liverpool John Moores University (Other)
Overall Status
Completed
CT.gov ID
NCT04979702
Collaborator
(none)
86
1
2
23
3.7

Study Details

Study Description

Brief Summary

The investigators aim to undertake a feasibility randomised controlled trial (RCT) to investigate whether mHealth technology, allowing biometric informed feedback and coaching on exercise and PA, can be effective in previously sedentary individuals. The overall objective is to have an evidence-based exercise and PA intervention ready to evaluate in a future RCT.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Active Control
  • Behavioral: mHealth technology assisted exercise counselling
N/A

Detailed Description

Participants will be recruited from Liverpool John Moores University, and other local office-based businesses. Participants will be randomised to either online exercise resources only (n=50) or exercise counselling + mHealth (n=50).This is a pilot parallel group, randomised controlled trial whereby consenting participants will complete baseline testing (T1) before starting a 12-week exercise intervention supported by online resources only (online resources intervention) or online resources and a programme of exercise counselling enhanced with mobile health (mHealth) technology (mHealth intervention). Participants will repeat baseline assessments (i) 6-weeks into the intervention (T2) and, (ii) immediately post-intervention (T3). Testing at baseline and following the 12-week intervention will include changes in physical activity, blood pressure, body composition and glycaemia control (n=20).

Both groups will have access to online resources throughout the 12-week programme. The intervention group will be provided with exercise counselling and to support this they will also be provide with a wristwatch that can monitor everyday activity and their heart rate, a smartphone app and access to a website. The intervention group will also participate in 4 consultations with an exercise specialist to plan their exercise programme and be updated on their progress towards physical activity targets. Weekly text message updates will also provide feedback to the intervention group with participants able to respond to these updates.

Study Design

Study Type:
Interventional
Actual Enrollment :
86 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomised controlled trialRandomised controlled trial
Masking:
None (Open Label)
Masking Description:
No masking
Primary Purpose:
Prevention
Official Title:
Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence
Actual Study Start Date :
Aug 1, 2020
Actual Primary Completion Date :
Apr 1, 2022
Actual Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active Control

Patients will have access to our online exercise resources throughout the 12-week intervention.

Behavioral: Active Control
Participants will complete a 3-month exercise and physical activity intervention supported by online recourses

Experimental: Experimental: mHealth technology assisted exercise counselling (mHealth)

Participants will complete a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.

Behavioral: mHealth technology assisted exercise counselling
Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology

Outcome Measures

Primary Outcome Measures

  1. Device derived adherence to structured exercise [Through study completion, an average 12 weeks]

    Number of exercise sessions per week

  2. Device derived duration to structured exercise [Through study completion, an average 12 weeks]

    minutes of exercise completed per session

  3. Device derived intensity of structured exercise [Through study completion, an average 12 weeks]

    intensity of exercise sessions performed (% of HR max)

  4. Change in Device derived physical activity (GENEActiv) [Baseline, Mid intervention (Week 6-7), the final 2 weeks of intervention period (weeks 10-12).]

    minutes of Moderate and Vigorous physical activity

  5. Change in Survey reported exercise behaviour (Godin Leisure Time Exercise Questionnaire (GLTEQ)) [Baseline, 4, 6, 8 12 weeks]

    Bouts of mild, moderate and strenuous exercise lasting ≥30 minutes

Secondary Outcome Measures

  1. Height [Baseline, 6-weeks and immediately following intervention (12 weeks)]

    Height (m)

  2. Weight [Baseline, 6-weeks and immediately following intervention (12 weeks)]

    Weight (kg)

  3. Waist Circumference [Baseline, 6-weeks and immediately following intervention (12 weeks)]

    Waist Circumference (cm)

  4. Concentration of Hba1c [Baseline and immediately following intervention (12 weeks)]

    Hba1c

  5. Blood Lipid concentrations [Baseline and immediately following intervention (12 weeks)]

    Total cholesterol, HDL/LDL, Triglycerides

  6. Glycaemic control [Baseline and immediately following intervention (12 weeks)]

    Flash glucose monitoring

  7. Patient qualitative survey on intervention acceptability [Immediately following intervention (12 weeks)]

    Study specific questionnaire (qualitative data)

  8. Patient qualitative survey on testing acceptability [7 Days following baseline testing]

    Study specific questionnaire (qualitative data)

  9. Exercise motivation [Baseline, Mid (week 6) and post (week 12)]

    Behavioural regulation in exercise questionnaire-2 (BREQ-2). Max score 76, min score 0, high score is better

  10. 12-Item Short Form Survey [Baseline, Mid (week 6) and post (week 12)]

    SF-12 Questionnaire (max 44 min 8, high score mean better outcome)

  11. Patient Interview to access intervention acceptability [Within 2 weeks of the end of the intervention]

    Patient interview

  12. Patient Interview to access testing acceptability [Within 2 weeks of the baseline testing]

    Patient interview

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male or female

  • Aged 18-75

  • No known cardiovascular or metabolic disorder (e.g. heart failure, diabetes, previous myocardial infarction etc.)

  • Able to exercise safely as deemed by completion of the PAR-Q+.

  • Not currently meeting the recommended exercise guidelines (150 minutes moderate or 75 minutes of vigorous intensity physical activity per week), as assessed during screening questions related to the participants previous activity levels.

Exclusion Criteria:
  • Aged <18 or >75

  • Pregnancy or planning to become pregnant in the next 3 months

  • <6 months postpartum or stopped breastfeeding <1 month before recruitment

  • Not owning a smartphone with a data plan or access to WiFi

Contacts and Locations

Locations

Site City State Country Postal Code
1 Liverpool John Moores University Liverpool United Kingdom L33AF

Sponsors and Collaborators

  • Liverpool John Moores University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Matthew Cocks, Lecturer in Muscle Biochemistry, Liverpool John Moores University
ClinicalTrials.gov Identifier:
NCT04979702
Other Study ID Numbers:
  • MotivateLJMU
First Posted:
Jul 28, 2021
Last Update Posted:
Aug 23, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Aug 23, 2022